DK1385577T3 - Anvendelse af NK-1-receptorantagonister mod godartet prostatahyperplasi - Google Patents

Anvendelse af NK-1-receptorantagonister mod godartet prostatahyperplasi

Info

Publication number
DK1385577T3
DK1385577T3 DK02719751T DK02719751T DK1385577T3 DK 1385577 T3 DK1385577 T3 DK 1385577T3 DK 02719751 T DK02719751 T DK 02719751T DK 02719751 T DK02719751 T DK 02719751T DK 1385577 T3 DK1385577 T3 DK 1385577T3
Authority
DK
Denmark
Prior art keywords
receptor antagonists
benign prostatic
prostatic hyperplasia
antagonists against
against benign
Prior art date
Application number
DK02719751T
Other languages
English (en)
Inventor
Susanne Buser
Anthony P D W Ford
Barbara Lenz
Andrew John Sleight
Pierre Vankan
Torsten Hoffmann
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK1385577T3 publication Critical patent/DK1385577T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK02719751T 2001-04-23 2002-02-02 Anvendelse af NK-1-receptorantagonister mod godartet prostatahyperplasi DK1385577T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01109853 2001-04-23

Publications (1)

Publication Number Publication Date
DK1385577T3 true DK1385577T3 (da) 2006-08-21

Family

ID=8177209

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02719751T DK1385577T3 (da) 2001-04-23 2002-02-02 Anvendelse af NK-1-receptorantagonister mod godartet prostatahyperplasi

Country Status (17)

Country Link
US (1) US20030004157A1 (da)
EP (1) EP1385577B1 (da)
JP (1) JP4146730B2 (da)
KR (1) KR100599134B1 (da)
CN (1) CN100398106C (da)
AR (1) AR035935A1 (da)
AT (1) ATE323531T1 (da)
AU (1) AU2002250876B2 (da)
BR (1) BR0209151A (da)
CA (1) CA2444395C (da)
DE (1) DE60210760T2 (da)
DK (1) DK1385577T3 (da)
ES (1) ES2261657T3 (da)
MX (1) MXPA03009720A (da)
PT (1) PT1385577E (da)
WO (1) WO2002085458A2 (da)
ZA (1) ZA200308110B (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002259147A1 (en) * 2001-05-08 2002-11-18 Schering Corporation Use of neurokinin receptor antagonists to treat androgen-dependent diseases
US6849624B2 (en) * 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides
ATE366576T1 (de) * 2003-01-31 2007-08-15 Hoffmann La Roche Neue kristallmodifikation von 2-(3,5-bis- trifluormethyl-phenyl)-n-6-(1,1-dioxo-1lamda-6-
NZ544244A (en) * 2003-07-03 2008-10-31 Hoffmann La Roche Dual NK1/NK3 antagonists for treating schizophrenia
ES2246687B2 (es) * 2004-02-11 2006-11-16 Miguel Muñoz Saez Utilizacion de antagonistas no peptidicos de receptores nk1 para la produccion de apoptosis en celulas tumorales.
JP4580426B2 (ja) 2004-07-06 2010-11-10 エフ．ホフマン−ラ ロシュ アーゲー Ｎｋ−１受容体拮抗薬の合成において中間体として使用されるカルボキサミド誘導体の製造方法
US20060030600A1 (en) * 2004-08-06 2006-02-09 Patrick Schnider Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
KR20070094666A (ko) 2005-02-25 2007-09-20 에프. 호프만-라 로슈 아게 약제 물질 분산성이 향상된 정제
ES2439736T3 (es) 2005-11-08 2014-01-24 Vertex Pharmaceuticals Incorporated Moduladores heterocíclicos de transportadores de casete de unión a ATP
US7671221B2 (en) 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US7754739B2 (en) 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
EP2117538A1 (en) 2007-01-24 2009-11-18 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
CN104447716A (zh) 2007-05-09 2015-03-25 沃泰克斯药物股份有限公司 Cftr调节剂
CA2989620C (en) 2007-12-07 2022-05-03 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
CN101910156B (zh) 2007-12-07 2013-12-04 沃泰克斯药物股份有限公司 3-(6-(1-(2,2-二氟苯并[d][1,3]间二氧杂环戊烯-5-基)环丙烷甲酰氨基)-3-甲基吡啶-2-基)苯甲酸的固体形式
EP2271622B1 (en) 2008-02-28 2017-10-04 Vertex Pharmaceuticals Incorporated Heteroaryl derivatives as CFTR Modulators
GB0808747D0 (en) 2008-05-14 2008-06-18 Glaxo Wellcome Mfg Pte Ltd Novel compounds
KR20110136813A (ko) 2009-03-17 2011-12-21 다이이찌 산쿄 가부시키가이샤 아미드 유도체
WO2010119347A1 (en) * 2009-04-14 2010-10-21 Helsinn Healthcare S.A. Netupitant for use in treating bladder dysfunction
WO2011053522A1 (en) * 2009-10-29 2011-05-05 Merck Sharp & Dohme Corp. Tertiary amide orexin receptor antagonists
DK3150198T3 (da) 2010-04-07 2021-11-01 Vertex Pharma Farmaceutiske sammensætninger af 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioxol-5-yl)-cyclopropancarboxamido)-3-methylpyriodin-2-yl)benzoesyre og indgivelse deraf
KR20160078997A (ko) 2013-11-08 2016-07-05 깃세이 야쿠힌 고교 가부시키가이샤 카복시메틸피페리딘 유도체
US10231932B2 (en) 2013-11-12 2019-03-19 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases
TWI649307B (zh) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
JP6494757B2 (ja) 2014-11-18 2019-04-03 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ ハイスループット試験高速液体クロマトグラフィーを行うプロセス
CN111741755B (zh) * 2018-02-02 2024-04-16 尤斯特拉里斯制药有限公司（以普雷舒拉纽罗作为商号） 肠胃外制剂及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6175013B1 (en) * 1994-06-10 2001-01-16 Eli Lilly And Company Imidazolinyl tachykinin receptor antagonists
FR2729951B1 (fr) * 1995-01-30 1997-04-18 Sanofi Sa Nouveaux composes heterocycliques, procede pour leur preparation et compositions pharmaceutiques en contenant
AU8692698A (en) * 1997-08-06 1999-03-01 Eli Lilly And Company 2-acylaminopropanamines as tachykinin receptor antagonists
TR200000291T2 (tr) * 1997-08-06 2000-07-21 Eli Lilly And Company Taşikinin reseptör antagonistleri olarak 2-asilaminopropanaminler.
JPH11322748A (ja) * 1998-03-19 1999-11-24 Takeda Chem Ind Ltd 複素環化合物、その製造法および用途
ATE496032T1 (de) * 1999-02-24 2011-02-15 Hoffmann La Roche 4-phenylpyridinderivate und deren verwendung als nk-1 rezeptorantagonisten
WO2000067742A2 (en) * 1999-05-05 2000-11-16 Warner-Lambert Company Use of gaba analogues for the modulation of substance p
RS50932B (sr) * 2000-07-14 2010-08-31 F. Hoffmann-La Roche Ag. N-oksidi kao prolekovi 4-fenil-piridinskih derivata koji su antagonisti nk1 receptora
US6849624B2 (en) * 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides

Also Published As

Publication number Publication date
ES2261657T3 (es) 2006-11-16
JP4146730B2 (ja) 2008-09-10
ZA200308110B (en) 2005-03-30
JP2004529931A (ja) 2004-09-30
AR035935A1 (es) 2004-07-28
WO2002085458A2 (en) 2002-10-31
BR0209151A (pt) 2004-07-13
MXPA03009720A (es) 2004-01-29
KR20040007503A (ko) 2004-01-24
EP1385577A2 (en) 2004-02-04
EP1385577B1 (en) 2006-04-19
DE60210760D1 (de) 2006-05-24
KR100599134B1 (ko) 2006-07-12
PT1385577E (pt) 2006-08-31
US20030004157A1 (en) 2003-01-02
CA2444395C (en) 2010-12-21
CA2444395A1 (en) 2002-10-31
WO2002085458A3 (en) 2003-10-30
CN100398106C (zh) 2008-07-02
CN1503684A (zh) 2004-06-09
DE60210760T2 (de) 2006-11-23
ATE323531T1 (de) 2006-05-15
AU2002250876B2 (en) 2005-03-03

Similar Documents

Publication Publication Date Title
DK1385577T3 (da) Anvendelse af NK-1-receptorantagonister mod godartet prostatahyperplasi
DK1278350T3 (da) Autentificering af verificering for mobilbrugere
DK1345920T3 (da) Hidtil ukendte sulfamider og anvendelse deraf som endothelinreceptorantagonister
DK1339678T3 (da) Selektive agonister til EP4-receptor til behandling af osteoporose
DK1307181T3 (da) Hidtil ukendte sammensætninger af minoxidil
NO20053783D0 (no) Behandling av godartet prostatahyperplasi
IS6289A (is) thríhringja hindrar af poly (ADP-ribosa) polymerösum
NO20030471D0 (no) Karboksamidforbindelser og deres anvendelse som antagonister for en 11CBY-reseptor
DE60120419D1 (de) 4-phenyl-pyridin-derivate verwendbar als neurokinin-1 rezeptor antagonisten
ATE368659T1 (de) Thrombinrezeptorantagonisten
DK1505998T3 (da) Forbedret anvendelse af hop-syrer som antimikrobielle midler
DK1157005T3 (da) 3-phenylpyridinderivater og anvendelsen deraf som NK-1-receptorantagonister
DK1170288T3 (da) Diphenylurinstofderivater og deres anvendelse som alfa2/5-HT2c-antagonister
DK1373256T3 (da) CCR5-antagonister, der er nyttige til behandling af AIDS
DK1458447T3 (da) Kombination af cytokrom-p450-beroende proteasinhibitorer
DK1354027T3 (da) Stabilisering af drikkevarer
DE60222693D1 (de) Nk1-antagonisten
NO20041968L (no) Anvendelse av cystationin
DK1276721T3 (da) Methylering af indolforbindelser under anvendelse af dimethylcarbonat
DK1296961T3 (da) 1,4-diazepan-2,5-dionderivater og anvendelse deraf som NK-1-receptorantagonister
IS2725B (is) Inndælingarlausn sem samanstendur af LHRH mótlyfi
DK1408964T3 (da) Hidtil ukendt anvendelse af 2-5-(4-fluorphenyl)-3-pyridylmethylaminomethyl-chroman og fysiologisk acceptable salte deraf
NO20023785D0 (no) Vanndispergerbar formulering av paroxetin
DK1268482T3 (da) Pyranoindoler til behandling af glaukom
DE60222015D1 (de) Ccr-3-rezeptorantagonisten vii